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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progres-
sive and lethal disease of the lungs characterized
by the proliferation of fibroblasts and deposition of
extracellular matrix (1-3). The recent progress in
the understanding of molecular pathogenesis in IPF
is characterized as the identification of the novel ori-
gin of lung fibroblasts in addition to resident fibro-
blasts including bone-marrow derived circulating
fibrocytes and fibroblasts derived from the epithelial-
to-mesenchymal transition (EMT)(4-8). To control
the novel subsets of lung fibroblasts might lead to
the development of a useful therapeutic strategy
for IPF.
A number of studies have demonstrated the poten-
tial for bone marrow (BM)-derived circulating fibro-
cytes to enter tissues following injury and contribute
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to wound healing and fibrosis (9-13). Fibrocytes
constitute approximately 0.5% of the peripheral
blood leukocyte population that shows an adherent
spindle shape in culture (10). They express mark-
ers of haematopoietic cells (CD34), leukocytes
(CD11b, CD13 and CD45) as well as fibroblast
products (collagens I, III, and fibronectin) (9-13).
They appear to be derived from the differentiation
of CD14+ peripheral blood mononuclear cells (9-
11) and differentiate into fibroblasts/myofibroblasts
under the control of TGF-β (10-12). The number
of BM-derived fibroblasts and fibrocytes recruited
into the injured lung can reach up to 10% and 25%
of fibroblasts (13). Furthermore the marked expan-
sion of circulating fibrocyte pool in patients with
interstitial pneumonia and the positive correlation
between the abundance of fibroblastic foci and the
amount of lung fibrocytes in patients with IPF
were reported (14, 15). The mechanisms involved
in the trafficking of fibrocytes have been reported
to be several chemokines/chemokine receptors in-
cluding CXCL12/CXCR4, CCL21/CCR7, CCL2/
CCR2 and CCL3/CCR5 (4, 5, 16-18). In particular,
CXCL12/CXCR4 axis is thought to be a main axis
to regulate the migration of fibrocytes in vitro and
in vivo (4, 5).
We therefore hypothesized whether blockade of
CXCR4 might inhibit the recruitment of fibrocytes
into injured lungs and the subsequent pulmonary
fibrosis. In the present study, we demonstrated
that CXCR4 antagonist AMD3100 reduced pulmo-
nary fibrosis via inhibiting the migration of fibroc-
tytes. These results suggest that CXCR4 antagonist
could be a novel therapy for patients with pulmo-
nary fibrosis.
METHODS
Mice and Material
Seven-week-old C57BL/6 female mice were pur-
chased from Charles River Japan, Inc. (Yokohama,
Japan). Mice were maintained in the animal facility
of the University of Tokushima under specific patho-
gen free conditions according to the guidelines of
our university (19). AMD3100 was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Bleomycin
was purchased from Nippon Kayaku Co. (Tokyo,
Japan). Recombinant human CXCL12 was pur-
chased from R&D systems, Inc. (Minneapolis,
MN, USA). PE -conjugated anti -mouse CXCR4
antibody, PE-Cy5 conjugated anti-mouse CD45
antibody (BD Biosciences-Pharmingen, San Diego,
California, USA), anti-collagen type I (Rockland,
Gilbertsville, Pennsylvania, USA), BD Cytofix/
CytoPerm Plus Kit (BD Biosciences-Pharmingen),
Collagenase IV (Gibco 17104-019), DEOXYRIBO-
NUCLEASE (DNase) I (CALBIOCHEM, Madison,
WI, USA) was used in this study.
Bleomycin and AMD3100 treatment
Mice were anesthesized with sodium pentobar-
biturate, and osmotic minipumps (model 2001, Alza
Pharmaceuticals, Palo Alto, CA, USA) containing
200 μl of saline with or without 125 mg/kg of bleo-
mycin (Nippon Kayaku Co., Tokyo, Japan) were im-
planted subcutaneously in the left suprascapular
lesion through an incision at the base of the neck
(19-21). Bleomycin was constantly infused from the
minipumps over 7 days as described in the manu-
facturer’s guidelines. This model showed the inflam-
mation in the early phase (from days 0 to 14) and
the fibrosis in the late phase (from days 14 to 28)
(19). The fibrotic lesions were observed mainly in
the subpleural area with patchy distribution. As a
control experiment, minipumps containing saline
only were also used. AMD3100 was also adminis-
tered using osmotic minipump from day 0 to 28.
Body weight of mice was measured every three to
four days. Each experiment was performed in at
least five mice per group.
Histopathology
The left lungs were inflated with 0.5 ml of 10%
buffered Formalin and fixed, followed by embed-
ding in paraffin. Sections (3 to 4 μm) were stained
with hematoxylin and eosin, and then examined
by light microscopy. For the quantitative histologi-
cal analysis of fibrotic changes induced by bleomy-
cin, a numerical fibrotic scale was used (Ashcroft
score) (22). In order to avoid observer’s bias, all
histological specimens were randomly numbered
and interpreted in a blind fashion by two patholo-
gists. The severity of the fibrotic changes in each
lung section was assessed as a mean score of se-
verity from observed microscopic fields. Fifteen
fields within each lung section were randomly se-
lected and evaluated at a magnification of x100.
Each field was assessed individually for the sever-
ity of fibrotic changes and given a score of 0 (nor-
mal) to 8 (total fibrosis). Briefly, the graded score
from 0 to 8 was defined as follows : Grade 0=
normal lung ; Grade 1=minimal fibrous thickening
of alveolar or bronchiolar walls ; Grade 3=moderate
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thickening of the walls without obvious damage to
the lung architecture ; Grade 5=increased fibrosis
with definite damage to the lung structure and the
formation of fibrous bands or small fibrous
masses ; Grade 7=severe distortion of the lung
structure and large fibrous areas ; Grade 8=total fi-
brous obliteration of the field. If there was any dif-
ficulty in deciding between two odd-numbered cate-
gories, the field was given the intervening even-
numbered grade. The mean score of all evaluated
fields was considered the fibrotic score. To further
evaluate the fibrotic changes, Masson’s-trichrome
staining was performed.
Collagen assay
The total amount of collagen in the right lungs
was determined using the Sircol Collagen Assay
kit (Biocolor, Northern Ireland) according to the
manufacturer’s instructions (19, 21). The Sircol dye
reagent contains Sirius Red, which is an anionic dye
with sulfonic acid side chain groups. These groups
react with the side chain groups of the basic amino
acids present in collagen. The specific affinity of
the dye for collagen under the assay conditions is
due to the elongated dye molecules becoming
aligned parallel with the long, rigid structure of
native collagen molecules that have an intact triple
helix organization. Briefly, the right lungs were har-
vested on day 28 after implantation of the minipump
containing bleomycin and homogenized in 0.5 M
acetic acid (50 volumes to wet lung weight) con-
taining about 1 mg pepsin/10 mg tissue residue.
Each sample was incubated for 24 hours at room
temperature with stirring. After centrifugation, 100
μl of each supernatant was assayed. One milliliter
of Sircol dye reagent, which binds to collagen, was
added to each sample, and the mixtures were mixed
for 30 minutes. After centrifugation, the pellets were
suspended in 1 ml of the alkaline reagent included
in the kit and the absorbance at 540 nm was read
using a spectrophotometer. Collagen standard so-
lutions were utilized to construct a standard curve.
Collagens contain about 14% hydroxyproline by
weight, and the collagen content obtained with this
method correlates well with hydroxyproline con-
tent according to the manufacturer’s data, and was
expressed as the collagen content of the right lung
(μg/lung).
Bronchoalveolar Lavage
Bronchoalveolar lavage was performed five times
with saline (1 ml) using a soft cannula (23). After
counting cell number of the bronchoalveolar lav-
age fluid, cells were cytospun onto glass slides and
stained with Diff-Quick (Baxter, Miami, FL, USA)
for cell classification.
Purification of fibrocytes
Human fibrocytes were isolated according to pre-
viously published methods (5). Peripheral blood
mononuclear cells (PBMCs) were isolated from
human peripheral blood by using Ficoll density
centrifugation (24). PBMCs were then cultured in
DMEM supplemented with 20% FBS for 7 days.
Typically, 5107 PBMCs were plated into each fi-
bronectin coated flask. The adherent cells were
harvested by using 0.125% tripsin. We used im-
munomagnetic selection to deplete B lympho-
cytes (anti-CD19 ; Miltenyi Biotech, Auburn, CA,
USA), T lymphocytes (anti-CD3 : Miltenyi Biotech),
and monocytes/macrophages (anti-CD14 : Miltenyi
Biotech) from our crude fibrocyte preparation. The
trypsinized cells were stained with anti-CD19, CD3,
CD14 Abs coupled to magnetic beads. Labeled cells
were then depleted by positive selection columns
using AutoMacs (Miltenyi Biotech). The negatively
selected cells were collected and used as human
fibrocytes.
Murine fibrocytes were isolated according to
previously published methods (4). The lungs were
harvested from saline or BLM-treated mice on day
7 and minced with razor blades. The minced lungs
were treated with collagenase IV and DNase I to
produce single cell suspensions and then cultured
in fibronectin-coated 10 cm-dish for 7 days. Finally
adherent cells were harvested and stained with
PE-Cy5 labeled anti-mouse CD45 Ab. Subsequently,
the cells were fixed in 10% neutral buffered forma-
lin, permeabilized by 0.3% saponin and then stained
with biotin-conjugated anti-mouse collagen-I Ab,
followed by Streptavidin-FITC. The stained cells
were analyzed by flow cytometry. The CD45+Colla-
gen I+ cells were counted as murine fibrocytes in
this study.
Flow cytometric analysis
Cells isolated from human peripheral blood were
stained with FITC-labeled anti-CD45 and CXCR4
antibodies. The stained cells were performed on a
FACScan flow cytometer (BD Biosciences- Pharm-
ingen, San Diego, California, USA) using Cellquest
3.2.1f1 software. Single cell suspensions from lung
tissue of bleomycin-treated mice were initially stained
with PE-Cy5 labeled CD45. Subsequently, the cells
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were permeabilized using cytofix/cytoperm (BD
Biosciences-Pharmingen) and were stained with
anti-Collagen I Ab prelabeled with Alexa488 by us-
ing Alexa488 labeling kit. Two-color analysis of the
stained cells was performed on a FACScan flow
cytometer.
Chemotaxis
Chemotaxis on cells at 1105 /well was per-
formed in Boyden chambers to DMEM contained
with 0.1% FBS or CXCL12 through collagen-coated
8 μm filters. Migration was assessed by counting
the number of cells in five high-power fields with
a light microscope.
Statistical analysis
Comparisons among multiple groups were made
using one-way ANOVA with Newman-Keuls post
hoc correction (GraphPad Prism, version 4.0).
Differences were considered statistically significant
if p values were less than 0.05.
RESULTS
Time kinetics of CXCL12 and fibrocytes in the lungs
treated with bleomycin
First we analyzed the levels of CXCL12 in bron-
choalveolar lavage fluid (BALF) of mice treated
with bleomycin by ELISA. As shown in figure 1A,
the levels of CXCL12 elevated from day 7 after bleo-
mycin administration, and the high level continued
until day 28. On the other hand, the number of fi-
brocytes was measured by flow cytometry using
double staining of CD45 and collagen I. As shown
in figure 1B, CD45+Collagen I+ fibrocytes was in-
creased from day 4 and reached the peak on day
7, and then gradually decreased until day 21.
Figure 1 Time course of CXCL12 and fibrocytes in the lungs treated with bleomycin. Mice were treated with osmotic minipumps
containing bleomycin. A : CXCL12 in bronchoalveolar lavage fluid (BALF) in mice treated with bleomycin. The BALF was harvested
on days 3, 7, 14, 21 and 28. CXCL12 in BALF was measured by ELISA. Data are shown as the meanSD of four mice. B : The per-
centage of fibrocytes in the lungs of mice treated with bleomycin. The lungs treated with bleomycin were harvested on days 0, 3, 7,
10, 14 and 21. The single cell suspensions were collected from the minced lungs. Then the cells were cultured on the dishes and the
adherent cells were harvested. The double staining with anti -CD45 and collagen I antibodies were performed for flow cytometric
analysis with adherent cells. The CD45+Collagen I+ cells were counted as murine fibrocytes in this study. The Data are shown as the
meanSD of four mice.
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CXCR4 antagonist AMD3100 improves weight loss
induced by bleomycin in mice
Next, we examined the in vivo effects of a CXCR4
antagonist AMD3100 on weight loss induced by
bleomycin in mice. The mice injected with bleo-
mycin (125 mg/kg) showed a significant loss of
body weight until day 14 as compared with those
injected with saline, and weight loss gradually re-
covered from day 18. In contrast, mice treated with
both bleomycin and AMD3100 showed a similar
weight loss on day 14, but their weight quickly
recovered from day 14 (Figure 2). On day 28,
AMD3100 (3 mg/kg/day and 6 mg/kg/day) signifi-
cantly improved the weight loss caused by bleomy-
cin. Mice treated with 6 mg/kg/day of AMD3100
showed better tendency of recovery response as
compared with mice treated with 3 mg/kg/day
AMD3100, but there were no significant differ-
ences between two groups. On the other hand,
mice treated with AMD3100 alone did not show
any loss of body weight, indicating that 6 mg/kg/
day of AMD3100 was not toxic to mice.
Administration of AMD3100 ameliorates bleomycin-
induced lung fibrosis in mice
The fibrotic change in the lung was evaluated
by histological examination and measurement of
total collagen content. As shown in Figure 3, ad-
ministration of AMD3100 alone did not generate
any changes in lung morphology, indicating that
AMD3100 did not show any adverse effects on the
lungs. However, when AMD3100 was administered
daily to bleomycin-treated mice, a significant reduc-
tion of fibrosis in the lungs was observed (Figure
3). These antifibrotic effects of AMD3100 were also
confirmed by histological examination using the
fibrotic score as described in the Methods section
(Figure 4A). The collagen assay demonstrated that
treatment with AMD3100 dose-dependently re-
duced the production of total collagen in bleomycin-
treated lungs (Figure 4B). More than 3 mg/kg/
day of AMD3100 were effective in reducing the
pulmonary fibrosis caused by bleomycin.
Figure 2 Effect of AMD3100 on weight loss of mice treated with bleomycin. Mice were treated with osmotic minipumps contain-
ing bleomycin (BLM). AMD3100 (3 mg/kg/day or 6 mg/kg/day) was given by using osmotic minipump. The change in body weight of
mice treated with saline alone (n=5), AMD3100 (6 mg/kg/day) (n=5), Bleomycin alone (n=8), Bleomycin+AMD3100 (3 mg/kg/
day) (n=8) or bleomycin+AMD3100 (6 mg/kg/day) (n=8) were examined. Similar results were obtained in two separate experi-
ments. *p0.05 versus bleomycin alone, p0.01 versus bleomycin alone.
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Figure 3 Histological examination of the antifibrotic effects of AMD3100 in bleomycin-induced pulmonary fibrosis. Mice were
treated with osmotic minipumps containing saline or bleomycin (BLM). AMD3100 (3 mg/kg/day or 6 mg/kg/day) was given sub-
cutaneously by using osmotic minipump for the entire duration of the experiment. On day 28, mice were sacrificed and histological
examination was performed by H&E staining (A-E) and Masson’s- trichrome staining (F-J) (original magnification : x40). A, F :
saline alone ; B, G : saline+AMD3100 (6 mg/kg/day) ; C, H : bleomycin alone ; D, I : bleomycin+AMD3100 (3 mg/kg/day) ; E, J :
bleomycin+AMD3100 (6 mg/kg/day). Data are representative of three separate experiments. Bar=200 μm.
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Effect of AMD3100 on cell analysis of BALF of
mice treated with bleomycin
Next, we analyzed the cells in BALF to evaluate
the effect of AMD3100 on the inflammatory re-
sponses induced by bleomycin. Administration of
bleomycin elevated the number of inflammatory
cells, including macrophages, lymphocytes and
neutrophils, on days 7, 14 and 28. Analysis of cell
classification also showed that bleomycin treatment
enhanced the percentage of lymphocytes and neu-
trophils on day 7, 14 and 28. Although administra-
tion of AMD3100 significantly reduced the percent-
age of lymphocytes in BALF on 14, AMD3100 did
not affect the early inflammation in BALF on day 7
(Table 1).
Figure 4 Quantitative examinations of the antifibrotic effects of AMD3100 on bleomycin-induced pulmonary fibrosis. Mice were
treated with osmotic minipumps containing saline or bleomycin (BLM). AMD3100 (3 mg/kg/day or 6 mg/kg/day) was given by using
osmotic minipump for the entire duration of the experiment. Mice were sacrificed on day 28. A : Evaluation of fibrotic change in the
lung using numerical fibrotic score. Histological examination in the left lung was performed by H&E staining. The fibrotic score was
determined by two pathologists as described in the Methods. Data are presented as meanSD of all fields examined in each group
of mice treated with saline alone (n=5), AMD3100 (6 mg/kg/day) (n=5), Bleomycin alone (n=8), Bleomycin+AMD3100 (3 mg/
kg/day) (n=8) or bleomycin+AMD3100 (6 mg/kg/day) (n=8). B : Effects of AMD3100 on collagen deposition after treatment with
bleomycin. Collagen content in the right lung was measured using a Sircol collagen kit. Data are presented as meanSD of mice.
Data are representative of two separate experiments. *p0.05 versus bleomycin alone, p0.001 versus bleomycin alone.
Table 1 Effects of AMD3100 on cell classification of bronchoalveolar lavage fluid
Days after treatment Total cells (106)
Cell differentiation (%)
Macrophages Lymphocytes Neutrophils
Day 0 0.310.15 95.62.07 3.001.73 1.400.54
Day 7
BLM 1.850.26 73.35.68 5.331.52 21.34.16
BLM+AMD3100 2.450.35 67.34.16 5.001.00 15.27.25
Day 14
BLM 4.271.53 67.64.97 29.24.65 3.201.48
BLM+AMD3100 3.741.51 85.02.70 12.52.38※ 2.502.51
Day 28
BLM 1.880.57 79.24.76 19.84.43 1.201.09
BLM+AMD3100 1.360.89 79.55.25 16.04.76 4.253.30
Mice were treated with mini -osmotic pump containing bleomycin (BLM) and AMD3100 (6 mg/kg/day). On day 0, 7, 14 and 28,
bronchoalveolar lavage was performed as described in methods. Data are presented as meanSD in the group of 6 mice. Similar
results were obtained in three separate experiment. *p0.01 v.s. percentage in BLM+AMD3100 group
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Effects of AMD3100 on the chemotaxis of human
fibrocytes in response to CXCL12 in vitro
Next we examined whether AMD3100 inhibited
the migration of human fibrocytes stimulated with
CXCL12. Human fibrocytes were generated from pe-
ripheral blood mononuclear cells. These fibrocytes
expressed CD45, CXCR4 and collagen I as previ-
ously described (figure 5A). Human fibrocytes mi-
grated in response to CXCL12 in a dose-dependent
manner (Figure 5B). Treatment with AMD3100 sig-
nificantly inhibited the migration of human fibro-
cytes (Figure 5B).
Treatment with AMD3100 reduces migration of
fibrocytes into the lungs in vivo
Finally, we examined whether AMD3100 could
inhibit the migration of fibrocytes into the lungs of
bleomycin-treated mice. Administration of AMD3100
(6 mg/kg/day) significantly inhibited the number
of CD45+Collagen I+ fibrocytes in the lungs of mice
treated with bleomycin on day 7 (bleomycin : 28.6
10.6% vs bleomycin+AMD3100 : 8.06.9 ; p0.05)
(figure 6).
DISCUSSION
In the present study, we demonstrated the anti-
fibrotic effects of CXCR4 antagonist AMD3100 in
bleomycin-induced pulmonary fibrosis in mice.
AMD3100 showed the inhibitory effects of migra-
tion of fibrocytes in response to CXCL12 in vitro
and in vivo . These results suggest the potential of
AMD3100 to be an antifibrotic drug for treatment
of patients with pulmonary fibrosis.
Circulating fibrocytes are thought to contribute
organ fibrosis and wound healing (25). In the pul-
monary fibrosis, Hashimoto et al. reported the con-
tribution of bone marrow-derived cells in bleomy-
cin-induced pulmonary fibrosis model (4). Phillips
et al. also demonstrated the CD45+CXCR4+Collagen
I+ cells play a role in pulmonary fibrosis induced
by bleomycin (5). Both reports indicated the criti-
cal role of CXCL12/CXCR4 axis for fibrocytes to
Figure 6 Administration of AMD3100 reduces the number of
fibrocytes into the lungs treated with bleomycin in mice. Mice
were implanted with osmotic minipumps containing bleomycin
(BLM). AMD3100 (6 mg/kg/day) was injected using osmotic
minipump. Single-cell suspensions were isolated from the lungs of
bleomycin-treated mice on day 7. After culturing in fibronectin-
coated 10 cm-dish, the adherent cells were stained for CD45 and
Collagen I, and examined by flow cytometry. A : Flow cytometric
analysis of fibrocytes. The data shows the double staining with
anti -CD45 and anti -collagen I antibodies for adherent cells of
the lungs of bleomycin-treated mice. B : The percentage of
CD45+Collagen I+ fibrocytes in bleomycin-treated lungs. Data are
shown as the meanSD of 4 mice. *p0.05, significant differ-
ences between bleomycin alone and bleomycin+AMD3100 (6
mg/kg/day).
Figure 5 AMD3100 inhibits migration of human fibrocytes in
response to CXCL12. A : Generation of human fibrocytes. Hu-
man fibrocytes were isolated from human peripheral blood mono-
nuclear cells as described in the Methods. Cell surface markers
of human fibrocytes were confirmed by flow cytometry. Human
fibrocytes were stained with control antibody (closed black)
and specific antibodies (open gray) for collagen I, CXCR4 and
CD45. B : Migration of human fibrocytes in response to CXCL12
and its inhibition by AMD3100. Fibrocytes(1104/well) were
added in upper chamber with or without AMD3100 (1 μg/ml).
Fibrocytes were tested for chemotaxis (n=3) to CXCL12 (10
and 100 ng/ml). Data are shown as the meanSD of three
wells. Similar results were obtained in four separate experiments.
*p0.001 versus CXCL12 (100 ng/ml) alone.
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migrate into the lungs. Other chemokine/chemokine
receptor systems are also known to play roles in
trafficking of fibrocytes, whereas CXCL12/CXCR4
could be main axis in pulmonary fibrosis. In fact,
CXCL12 was reported to be mostly expressed in
macrophages and airway epithelial cells in the fi-
brotic lungs (26). Therefore controlling migration
of fibrocytes by blockade of CXCR4 might lead to
reduce pulmonary fibrosis. In fact, Phillips et al.
showed that treatment with neutralizing antibody
of CXCL12 ameliorated bleomycin-induced pulmo-
nary fibrosis in mice (5). Thinking of clinical situ-
ation, a small molecule drug such as an inhibitor
or antagonist of CXCR4 might be more useful for
treatment of patients with pulmonary fibrosis. In the
present study, we used a small molecule antago-
nist AMD3100, which was clearly demonstrated to
be specific for CXCR4 and originally found to in-
hibit the replication of T-lymphotropic human im-
munodeficiency virus strains by blocking the entry
into T cells via CXCR4 (27, 28). Administration of
AMD3100 significantly reduced bleomycin-induced
pulmonary fibrosis in mice. In addition, AMD3100
improved weight loss of mice treated with bleomy-
cin in the late phase paralleled with the reduction
of pulmonary fibrosis. Recently, Song et al. reported
an inhibitory effect of CXC chemokine receptor 4
antagonist AMD3100 in bleomycin-induced pulmo-
nary fibrosis model (29). They reported the eleva-
tion of numbers of lymphocytes and macrophages
in bronchoalveolar lavage fluid (BALF). However,
our results showed that AMD3100 did not affect
the cells in BALF on day 7 and reduced the per-
centage of lymphocyte on day 14. The reason for
this discrepancy remains unclear, but might be due
to the difference in experimental systems used in
both studies. In our study, bleomycin was adminis-
tered systemically using osmotic minipump, but they
used intratracheal route of injection of bleomycin.
The systemic distribution of bleomycin more closely
reflects the drug-induced lung toxicity in clinic.
Since CXCR4 is expressed in some population of
lymphocytes, it is not surprising that AMD3100 in-
hibited the migration of lymphocytes into the lungs.
Regarding the antifibrotic effects of AMD3100,
our data was consistent to the report by Song et al.
and extend their results by using another experi-
mental method. In addition, AMD3100 significantly
reduced the migration of fibrocytes into the lungs
treated with bleomycin in mice. The direct effects
of AMD3100 on migration of fibrocytes were con-
firmed by using human fibrocytes. The in vivo
experiment also demonstrated the reduced number
of fibrocytes in the lungs treated with bleomycin
and AMD3100. However, inhibition of the number
of fibrocytes in the lungs by AMD3100 was partial,
indicating that the other factors such as other
chemokines may, at least in part, contribute to the
migration of fibrocytes into the lungs in vivo .
Recently, the number of fibrocytes in peripheral
blood of patients with pulmonary fibrosis is reported
to correlate with the parameters of respiratory func-
tion test as well as prognosis of patients (30, 31).
Further study would be required to understand the
role of fibrocytes in pulmonary fibrosis in clinic.
These results suggest that AMD3100 could be
an inhibitor of migration of fibrocytes and that treat-
ment with AMD3100 might be useful approach for
patients with pulmonary fibrosis.
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